• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA clears Elscint's TransACT protocol

Article

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct inferior wall artifactscommon in myocardial imaging with thallium. The company is planningto adapt the technique for the adjustable-angle Varicam cameraas well.

Elscint also announced this month that it has received clearancefor its 2-tesla Prestige MRI scanner.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.